Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) EBITDA (2016 - 2025)

Historic EBITDA for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $10.2 million.

  • Corcept Therapeutics' EBITDA fell 7806.99% to $10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.6 million, marking a year-over-year decrease of 5426.03%. This contributed to the annual value of $137.0 million for FY2024, which is 2765.52% up from last year.
  • Corcept Therapeutics' EBITDA amounted to $10.2 million in Q3 2025, which was down 7806.99% from $26.7 million recorded in Q2 2025.
  • Corcept Therapeutics' 5-year EBITDA high stood at $46.6 million for Q3 2024, and its period low was $3.4 million during Q1 2025.
  • For the 5-year period, Corcept Therapeutics' EBITDA averaged around $26.5 million, with its median value being $29.5 million (2024).
  • Its EBITDA has fluctuated over the past 5 years, first soared by 9861.31% in 2024, then tumbled by 8842.03% in 2025.
  • Corcept Therapeutics' EBITDA (Quarter) stood at $31.7 million in 2021, then dropped by 29.05% to $22.5 million in 2022, then surged by 40.76% to $31.7 million in 2023, then decreased by 20.23% to $25.3 million in 2024, then crashed by 59.55% to $10.2 million in 2025.
  • Its last three reported values are $10.2 million in Q3 2025, $26.7 million for Q2 2025, and $3.4 million during Q1 2025.